Trial Profile

International, Multi-center, Open-label, Treatment Extension Study in Patients With Multiple Myeloma Who Are Still Benefitting From Isatuximab-based Therapy Following Completion of a Phase 1, 2, or 3 Parental Study

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemiplimab (Primary) ; Dexamethasone (Primary) ; Isatuximab (Primary) ; Lenalidomide (Primary) ; Pomalidomide (Primary)
Indications Multiple myeloma
Focus Adverse reactions
Sponsors Sanofi; Sanofi-Aventis Recherche & Developpement

23 Jan 2025 Status changed from recruiting to active, no longer recruiting.
19 Jun 2024 Planned End Date changed from 21 Sep 2026 to 30 Nov 2026.
19 Jun 2024 Planned primary completion date changed from 21 Sep 2026 to 30 Nov 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com